1.Figueras F, Gardosi J. Intrauterine growth restriction: new concepts in antenatal surveillance, diagnosis, and management. Am J Obstet Gynecol. 2011;204(4):288–300.
2.Figueras F, Oros D, Cruz-Martinez R, Padilla N, Haernandez-Andrade E, Botet F, et al., editors. Neurobehavior in term, small-for-gestational age infants with normal placental function. peds; 2009.
3.Illa M, Coloma JL, Eixarch E, Meler E, Iraola A, Gardosi J, et al. Growth deficit in term small-for-gestational fetuses with normal umbilical artery Doppler is associated with adverse outcome. 2009;37(1):48–52.
4.Savchev S, Figueras F, Cruz‐Martinez R, Illa M, Botet F, Gratacos EJUiO, et al. Estimated weight centile as a predictor of perinatal outcome in small‐for‐gestational‐age pregnancies with normal fetal and maternal Doppler indices. 2012;39(3):299–303.
5.Comas M, Crispi F, Cruz-Martinez R, Figueras F, Gratacos EJAjoo, gynecology. Tissue Doppler echocardiographic markers of cardiac dysfunction in small-for-gestational age fetuses. 2011;205(1):57. e1-. e6.
6.Eixarch E, Meler E, Iraola A, Illa M, Crispi F, Hernandez‐Andrade E, et al. Neurodevelopmental outcome in 2‐year‐old infants who were small‐for‐gestational age term fetuses with cerebral blood flow redistribution. 2008;32(7):894–9.
7.Crispi F, Bijnens B, Figueras F, Bartrons J, Eixarch E, Le Noble F, et al. Fetal growth restriction results in remodeled and less efficient hearts in children. 2010.
8.Crispi F, Figueras F, Cruz-Lemini M, Bartrons J, Bijnens B, Gratacos EJAjoo, et al. Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity. 2012;207(2):121. e1-. e9.
9.Barker DJ, Osmond C, Winter P, Margetts B, Simmonds SJJTL. Weight in infancy and death from ischaemic heart disease. 1989;334(8663):577–80.
10.Zhang J, Merialdi M, Platt LD, Kramer MS. Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol. 2010;202(6):522–8.
11.Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev. 2009;85(10):653–8.
12.Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small- or large-for-gestational-age. Acta Paediatr. 2010;99(4):550–5.
13.Galan HL. Timing delivery of the growth-restricted fetus. Semin Perinatol. 2011;35(5):262–9.
14.von Beckerath AK, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P. Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol. 2013;208(2):130 e1–6.
15.Figueras F, Eixarch E, Gratacos E, Gardosi J. Predictiveness of antenatal umbilical artery Doppler for adverse pregnancy outcome in small-for-gestational-age babies according to customised birthweight centiles: population-based study. BJOG. 2008;115(5):590–4.
16.Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J, Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res. 2010;33(9):892–8.
17.Garovic VD. The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. Hypertension. 2012;59(3):555–7.
18.Ghosh SK, Raheja S, Tuli A, Raghunandan C, Agarwal S. Serum PLGF as a potential biomarker for predicting the onset of preeclampsia. Arch Gynecol Obstet. 2012;285(2):417–22.
19.Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem. 2012;58(5):837–45.
20.Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond). 2012;122(2):43–52.
21.Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–28.
22.Herraiz I, Droge LA, Gomez-Montes E, Henrich W, Galindo A, Verlohren S. Characterization of the soluble fms-like tyrosine kinase–1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124(2 Pt 1):265–73.
23.Deveci K, Sogut E, Evliyaoglu O, Duras NJJoO, Research G. Pregnancy‐associated plasma protein‐A and C‐reactive protein levels in pre‐eclamptic and normotensive pregnant women at third trimester. 2009;35(1):94–8.
24.Bersinger NA, Ødegård RAJAoegS. Second‐and third‐trimester serum levels of placental proteins in preeclampsia and small‐for‐gestational age pregnancies. 2004;83(1):37–45.
25.Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CWJHip. Women with preeclampsia have increased serum levels of pregnancy‐associated plasma protein A (PAPP‐A), inhibin A, activin A and soluble E‐selectin. 2003;22(1):45–55.
26.Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JMJTJoCE, et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. 2002;87(4):1762–7.
27.Poon L, Akolekar R, Lachmann R, Beta J, Nicolaides KJUiO, Gynecology. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks. 2010;35(6):662–70.